Comprehensive characterization and clinical impact of concomitant genomic alterations in EGFR-mutant NSCLCs treated with EGFR kinase inhibitors.
Lung Cancer(2020)
摘要
•Alterations in TP53, ERBB2 or FGF19 correlated with poorer prognosis in TKI1st treated NSCLCs.•EGFR-mutant and TP53-WT NSCLCs benefited more from the combined A + T therapy.•NSCLC patients with CNV correlated with a shorter PFS in response to TKI3rd.
更多查看译文
关键词
EGFR tyrosine kinase inhibitors,EGFR-mutant-NSCLC,Progression-free survival,Overall survival,Genomic alterations
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络